Cutaneous Side Effects of PD ‐1 Inhibitors: A Single‐Center Retrospective Study
International Journal of Dermatology · 2025-06 · 64 (6) · 1066-1078
DOI: 10.1111/ijd.17683 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Dermatology, online erschienen am 09.02.2025. Verfasst von Melánia Pozsgai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venerology and Oncodermatology Clinical Center, University of Pécs, Pécs, Hungary. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors, Nivolumab, Skin Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran, Thematic Excellence Program 2021 Health Sub-programme of the Ministry for Innovation and Technology in Hungary, within the framework of the EGA-10 project of t….
Abstract (Originalsprache)
Background
The introduction of immune checkpoint inhibitors (ICIs) opened a new era in cancer immunotherapy. In particular, PD‐1 inhibitors have shown remarkable efficacy in various cancers, most notably melanoma. However, the widespread use of immune checkpoint inhibitors comes with the challenge of immune‐related adverse events (irAEs), with cutaneous toxicities being the most prevalent.
Methods
A retrospective, single‐center study was carried out to investigate the cutaneous side effects in patients diagnosed with melanoma and treated with PD‐1 inhibitors (pembrolizumab or nivolumab) at the Department of Dermatology, Venereology, and Oncodermatology, University of Pécs, Hungary. The study included patients with stage III or IV melanoma who received PD‐1 inhibitor monotherapy, either for metastatic or adjuvant purposes, from August 2015 to May 2022.
Results
A cohort of 174 patients was examined, with 29% experiencing cutaneous adverse events (cAEs). The most prevalent cutaneous toxicities were vitiligo ( n = 18; 27%), maculopapular rash ( n = 14; 21%), pruritus ( n = 14; 21%), xerostomia ( n = 8; 12%), and lichenoid dermatitis ( n = 4; 6%). Treatment primarily involved topical corticosteroids and emollients, with a few cases requiring systemic therapy. Notably, the occurrence of dermatologic adverse events was associated with improved progression‐free survival (PFS) ( p = 0.007) and overall survival (OS) ( p = 0.026) compared to those without any skin toxicity ( p < 0.0001), emphasizing their potential prognostic significance. Our data were not influenced by any well‐known prognostic factors of melanoma.
Conclusion
Our study contributes to the growing body of evidence supporting the prognostic value of cutaneous adverse events in patients treated with PD‐1 inhibitors. Optimizing treatment strategies while maintaining oncologic therapy is essential, highlighting the role of dermatologists in multidisciplinary cancer care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Venerology and Oncodermatology Clinical Center, University of Pécs, Pécs, Hungary.
- Malta Foundation Program, Mater Dei Hospital, Msida, Malta.
- Department of Dermatology and Allergology, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary.
ORCID-Profile: Melánia Pozsgai
Förderung
- Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran
- Thematic Excellence Program 2021 Health Sub-programme of the Ministry for Innovation and Technology in Hungary, within the framework of the EGA-10 project of t…
Zitieren
APA
Pozsgai, M., Sebastian, U. F., Oláh, P., Németh, V., Gyulai, R., & Lengyel, Z. (2025). Cutaneous Side Effects of PD ‐1 Inhibitors: A Single‐Center Retrospective Study. International Journal of Dermatology, 64(6), 1066-1078. https://doi.org/10.1111/ijd.17683
Vancouver
Pozsgai M, Sebastian UF, Oláh P, Németh V, Gyulai R, Lengyel Z. Cutaneous Side Effects of PD ‐1 Inhibitors: A Single‐Center Retrospective Study. International Journal of Dermatology. 2025;64(6):1066-1078. doi:10.1111/ijd.17683
BibTeX
@article{Pozsgai2025,
author = {Pozsgai, Melánia and Sebastian, Udoh Frieda-Rex and Oláh, Péter and Németh, Viktória and Gyulai, Rolland and Lengyel, Zsuzsanna},
title = {Cutaneous Side Effects of PD ‐1 Inhibitors: A Single‐Center Retrospective Study},
journal = {International Journal of Dermatology},
year = {2025},
volume = {64},
number = {6},
pages = {1066--1078},
doi = {10.1111/ijd.17683}
}
EUVIMED